Opportunity Information: Apply for PAR 16 021
Apply for PAR 16 021
- The HHS-NIH11 in the health sector is offering a public funding opportunity titled "NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.233, 93.837, 93.838, 93.839,.
- This funding opportunity was created on Oct 30, 2015 and posted on Oct 30, 2015.
- Applicants must submit their applications by Jan 18, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 10 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01) opportunity (PAR 16-021) is a National Institutes of Health (NIH) program from the Department of Health and Human Services, aimed at accelerating research on common, complex disorders affecting the heart, lungs, and blood. The central idea is to connect rich clinical and phenotypic information with modern "omics" measurements, especially whole genome sequencing and other high-throughput molecular assays, so researchers can better understand the genetic basis of disease and identify omics-based signatures linked to disease risk, progression, and outcomes. This opportunity sits within the NHLBI TOPMed effort, which is known for generating large-scale, harmonized omics datasets that can be used broadly by the scientific community.
A key feature of this FOA is that it is an X01 mechanism, meaning it does not provide direct financial award dollars to applicants. Instead, successful projects gain access to NIH-funded omics capacity. In practical terms, investigators who already have well-characterized study populations and stored biospecimens can apply to have those samples processed using NIH-supported sequencing or other omics platforms. The "award" is essentially access to high-value omics data generation infrastructure, which can be difficult and expensive to obtain through standard funding routes. The expectation is that applicants contribute biospecimens suitable for the proposed assays, and that the project is designed to produce interpretable links between molecular data and the heart, lung, and blood traits or diseases being studied.
The scientific scope is focused on common, complex diseases and traits in the heart, lung, and blood domains, and the FOA explicitly encourages studies that examine either the genetic basis of these conditions, omics signatures associated with them, or both. "Omics" here can include whole genome sequencing and potentially other molecular profiling approaches, with the overarching goal of discovering variants, pathways, and multi-omic patterns that help explain disease biology. Projects are expected to be grounded in strong phenotype data so that downstream analyses can relate omics variation to clinically relevant endpoints and measurable traits.
Another central requirement is data sharing. The resulting omics data, along with related phenotypic data, are intended to be deposited into a public-access repository such as dbGaP (the NIH database of Genotypes and Phenotypes). This is meant to maximize scientific value by making the dataset available for secondary research, replication, and meta-analyses. Applicants should therefore be prepared for the governance, consent, and data management steps that come with sharing genomic and phenotypic information in controlled-access public databases, including ensuring that participant permissions and institutional policies support broad data use consistent with NIH expectations.
Eligibility is broad and includes many organization types across the public and private sectors. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities and Indian housing authorities; nonprofit organizations both with and without 501(c)(3) status; for-profit organizations (other than small businesses); and small businesses, as well as other entities as further clarified in the FOA text. The wide eligibility reflects the reality that valuable cohorts and biospecimen collections may be held by universities, health systems, public agencies, nonprofits, or private research organizations.
From an administrative standpoint, the opportunity is categorized as discretionary and uses the grant funding instrument type, under the health activity category. It is associated with CFDA numbers 93.233, 93.837, 93.838, and 93.839, aligning it with NHLBI and related NIH program areas. The FOA was posted on October 30, 2015, with an application closing date of January 18, 2019 (both original and current closing dates listed as the same). The FOA lists an expected number of awards around 10, and while an "award ceiling" field appears, the practical takeaway is that no direct funding is provided under this mechanism because the support comes in the form of NIH-provided omics services and data generation.
Overall, this grant opportunity is best understood as a way for investigators with strong cohorts, high-quality biospecimens, and well-defined heart, lung, or blood phenotypes to plug into NIH-supported sequencing and omics pipelines, generate high-impact datasets, and contribute those data back to the broader research ecosystem through repositories like dbGaP. It is designed to increase the scale and quality of omics-phenotype resources available for discovery science and to speed progress toward understanding and eventually improving prevention, diagnosis, and treatment of major cardiopulmonary and hematologic disorders.
FAQs: NHLBI TOPMed - Omics Phenotypes of Heart, Lung, and Blood Disorders (X01) (PAR 16-021)
What is the NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01) opportunity (PAR 16-021)?
This is a National Institutes of Health (NIH) opportunity from the Department of Health and Human Services (HHS), administered through the National Heart, Lung, and Blood Institute (NHLBI). It is part of the TOPMed (Trans-Omics for Precision Medicine) effort and is designed to accelerate research on common, complex disorders affecting the heart, lungs, and blood by connecting strong clinical/phenotypic information with modern "omics" measurements.
What is the main goal of this opportunity?
The goal is to link rich clinical and phenotypic datasets with omics data (especially whole genome sequencing and other high-throughput molecular assays) to better understand the genetic basis of disease and to identify omics-based signatures associated with disease risk, progression, and outcomes.
What does "TOPMed" mean in this context?
TOPMed refers to an NHLBI effort known for generating large-scale, harmonized omics datasets intended to be used broadly by the scientific community. This opportunity fits within that larger initiative by adding new omics data tied to well-characterized phenotypes.
What funding mechanism is used (X01), and what does it mean for applicants?
This opportunity uses the X01 mechanism. An X01 does not provide direct financial award dollars to applicants. Instead, the benefit to successful applicants is access to NIH-funded omics capacity, meaning NIH-supported sequencing or other omics data generation services.
Does this opportunity provide grant money to support the research?
No. The key feature of this FOA is that it does not provide direct funding to the applicant organization. The "award" is access to NIH-supported omics platforms and infrastructure to generate high-value omics data.
If there is no direct funding, what support do awardees actually receive?
Awardees receive access to NIH-funded omics data generation resources. In practical terms, investigators with existing, well-characterized study populations and stored biospecimens can apply to have those samples processed using NIH-supported sequencing or other high-throughput molecular assays.
Who is this opportunity best suited for?
It is best suited for investigators who already have well-characterized cohorts or study populations, strong phenotype and clinical data, and stored biospecimens suitable for the proposed omics assays, especially in the heart, lung, and blood domains.
What kinds of diseases and traits are within the scientific scope?
The scope focuses on common, complex diseases and traits affecting the heart, lungs, and blood. The FOA encourages studies that investigate the genetic basis of these conditions, omics signatures associated with them, or both.
What types of "omics" are emphasized?
The opportunity emphasizes whole genome sequencing and also references other high-throughput molecular assays. Overall, the intent is to discover variants, pathways, and multi-omic patterns that help explain disease biology and relate to clinically relevant endpoints.
What role does phenotype and clinical data play in this program?
Strong phenotypic and clinical data are central. Projects are expected to be grounded in well-defined phenotypes so that downstream analyses can connect omics variation to meaningful clinical endpoints and measurable traits.
What are applicants expected to contribute?
Applicants are expected to contribute biospecimens suitable for the proposed assays and to propose a project designed to produce interpretable links between molecular (omics) data and the heart, lung, or blood traits or diseases being studied.
Is data sharing required under this opportunity?
Yes. Data sharing is a central requirement. The resulting omics data, along with related phenotypic data, are intended to be deposited into a public-access repository such as dbGaP (the NIH database of Genotypes and Phenotypes).
What repository is specifically mentioned for data deposition?
dbGaP (the NIH database of Genotypes and Phenotypes) is specifically mentioned as an example of a public-access repository where omics and related phenotypic data are intended to be deposited.
Why does the FOA require depositing data into repositories like dbGaP?
The intent is to maximize scientific value by making the dataset available for secondary research, replication studies, and meta-analyses, thereby enabling broader community use and accelerating discovery.
What should applicants be prepared for regarding governance and participant permissions?
Applicants should be prepared for the governance, consent, and data management steps that come with sharing genomic and phenotypic information in controlled-access public databases. This includes ensuring participant permissions and institutional policies support broad data use consistent with NIH expectations.
Who is eligible to apply?
Eligibility is broad and includes many organization types across the public and private sectors, reflecting that valuable cohorts and biospecimen collections may be held in varied settings such as universities, health systems, public agencies, nonprofits, and private research organizations.
What government entities are eligible?
Eligible government applicants include state governments, county governments, city or township governments, and special district governments.
Are educational institutions eligible?
Yes. Eligible applicants include independent school districts, public and state-controlled institutions of higher education, and private institutions of higher education.
Are tribal governments and tribal organizations eligible?
Yes. Federally recognized Native American tribal governments and other tribal organizations are listed as eligible.
Are housing authorities eligible to apply?
Yes. Public housing authorities and Indian housing authorities are included among eligible applicants.
Are nonprofit organizations eligible?
Yes. Nonprofit organizations with and without 501(c)(3) status are listed as eligible.
Are for-profit organizations eligible?
Yes. For-profit organizations (other than small businesses) and small businesses are included among eligible applicants.
How is this opportunity categorized administratively?
It is categorized as discretionary and uses the grant funding instrument type, under the health activity category.
What CFDA numbers are associated with this opportunity?
The FOA is associated with CFDA numbers 93.233, 93.837, 93.838, and 93.839.
When was the FOA posted, and what is the application closing date?
The FOA was posted on October 30, 2015. The application closing date is listed as January 18, 2019 (with both original and current closing dates shown as the same date).
How many awards are expected?
The FOA lists an expected number of awards of around 10.
What does the "award ceiling" mean for an X01 like this?
Although an "award ceiling" field may appear, the practical takeaway for this FOA is that no direct funding is provided under the X01 mechanism because the support is delivered as NIH-provided omics services and data generation rather than applicant-held dollars.
What kind of outcomes is this program trying to enable?
The program is designed to generate high-impact omics datasets linked to strong phenotypes, enabling discovery of genetic variants, pathways, and omics-based signatures that relate to disease biology and clinically relevant outcomes for major cardiopulmonary and hematologic disorders.
How does this opportunity benefit the broader research community?
By generating large-scale omics data tied to well-characterized phenotypes and depositing those data into repositories like dbGaP, the program expands shared resources for secondary research, replication, and pooled analyses, helping speed progress across the field.
Browse more opportunities from the same category: Health
Next opportunity: Limited Competition: Pediatric Heart Network for the Data Coordinating Center (U24)
Previous opportunity: NEA Literature (Poetry) Fellowships, FY2017
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 16 021
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 16 021) also looked into and applied for these:
| Funding Opportunity |
|---|
| Limited Competition: Pediatric Heart Network for the Data Coordinating Center (U24) Apply for RFA HL 17 005 Funding Number: RFA HL 17 005 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Emergency Medical Services for Children Innovation and Improvement Center Apply for HRSA 16 052 Funding Number: HRSA 16 052 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Statewide Family Network Program Apply for SM 16 004 Funding Number: SM 16 004 Agency: HHS-SAMHS Category: Health Funding Amount: $95,000 |
| State Offices of Rural Health Grant Program (SORH) Apply for HRSA 16 016 Funding Number: HRSA 16 016 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Precision Medicine Initiative Cohort Program Healthcare Provider Organization Enrollment Centers (UG3/UH3) Apply for RFA PM 16 002 Funding Number: RFA PM 16 002 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| National State-Based Tobacco Control Programs Apply for CDC RFA DP15 150902CONT16 Funding Number: CDC RFA DP15 150902CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| NIH Director's Early Independence Awards (DP5) Apply for RFA RM 15 006 Funding Number: RFA RM 15 006 Agency: HHS-NIH11 Category: Health Funding Amount: $250,000 |
| Pre-clinical Research Based on Existing Repurposing Tools Apply for RFA TR 16 001 Funding Number: RFA TR 16 001 Agency: HHS-NIH11 Category: Health Funding Amount: $250,000 |
| Precision Medicine Initiative Cohort Program Participant Technologies Center (U24) Apply for RFA PM 16 003 Funding Number: RFA PM 16 003 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Noncommunicable Disease Prevention and Health Promotion in the Region of the Americas, PAHO Apply for CDC RFA GH15 161802CONT16 Funding Number: CDC RFA GH15 161802CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Pediatric Heart Network Clinical Research Centers (UG1) Apply for RFA HL 17 004 Funding Number: RFA HL 17 004 Agency: HHS-NIH11 Category: Health Funding Amount: $220,000 |
| MCH Pipeline Training Program Apply for HRSA 16 037 Funding Number: HRSA 16 037 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Ensuring Adequate Access to HIV/AIDS Screening, Care and Treatment to Key Populations in Haiti under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH16 1682 Funding Number: CDC RFA GH16 1682 Agency: HHS-CDC-CGH Category: Health Funding Amount: $1,200,000 |
| Supporting the National Blood Transfusion Service (NBTS) in the implementation and expansion of Blood Safety activities in the Republic of Zambia under the President’s Emergency plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH16 1709 Funding Number: CDC RFA GH16 1709 Agency: HHS-CDC Category: Health Funding Amount: $1,353,644 |
| Strengthening HIV/AIDS Prevention and Care Services for Highly Vulnerable Populations in the Republic of Côte d’Ivoire Under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS10 10310501SUPP16 Funding Number: CDC RFA PS10 10310501SUPP16 Agency: HHS-CDC Category: Health Funding Amount: $3,123,298 |
| National Child Traumatic Stress Initiative, National Center for Child Traumatic Stress Apply for SM 16 003 Funding Number: SM 16 003 Agency: HHS-SAMHS Category: Health Funding Amount: $6,000,000 |
| Service Area Competition – Additional Areas (SAC-AA) – California, District of Columbia, Kansas, Nevada, New York, Oregon, Texas, and Washington Apply for HRSA 16 176 Funding Number: HRSA 16 176 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Service Area Competition – Additional Area (SAC-AA) – Baltimore, Maryland Apply for HRSA 16 177 Funding Number: HRSA 16 177 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| B Cell Immunology Program for HIV-1 Vaccine Development (BCIP) (R01) Apply for RFA AI 15 055 Funding Number: RFA AI 15 055 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Supporting the Provision of High Quality, Comprehensive, and Sustainable HIV Services in National Teaching and Referral Hospitals in the Republic of Kenya under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH16 1621 Funding Number: CDC RFA GH16 1621 Agency: HHS-CDC-CGH Category: Health Funding Amount: $10,500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 16 021", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.